Crossmark

Significant association between joint ultrasonographic parameters and synovial inflammatory factors in rheumatoid arthritis

Crossref DOI link: https://doi.org/10.1186/s13075-018-1802-x

Published Online: 2019-01-10

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Kondo, Yasushi

Suzuki, Katsuya

Inoue, Yumiko

Sakata, Koumei

Takahashi, Chihiro

Takeshita, Masaru

Kassai, Yoshiaki

Miyazaki, Takahiro

Morita, Rimpei

Niki, Yasuo

Kaneko, Yuko

Yasuoka, Hidekata

Yamaoka, Kunihiro

Yoshimura, Akihiko

Takeuchi, Tsutomu
Funding

Funding for this research was provided by:

Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan (25461484)
License Information

Text and Data Mining valid from 2019-01-10
More Information

Article History

Received: 4 September 2018

Accepted: 20 December 2018

First Online: 10 January 2019

Ethics approval and consent to participate

: This study was approved by the ethics committee (number 20110258, 20130246, and 20140067) at Keio University Hospital.

: Not applicable,

: YaK has no competing interests. KaS has received research grants from Eisai, Bristol-Myers Squibb, Kissei Pharmaceutical, Daiichi-Sankyo. YK and TM are employees of Takeda Pharmaceutical Company Limited. TT has received research grants from Abbvie, Astra Zeneca, Bristol Myers Squibb, Chugai Pharmaceutical, Eisai Pharmaceutical, Janssen Pharmaceutical, Mitsubishi Tanabe Pharma Corporation, Novartis, Takeda Pharmaceutical, Abbott Japan Co., Ltd., Astellas Pharma, Ltd., Daiichi Sankyo, Pfizer, Sanofi–Aventis, Santen Pharmaceutical, Teijin Pharma Ltd., Asahikasei Pharma Corp., SymBio Pharmaceuticals Ltd., Celtrion, Nipponkayaku Co. Ltd., Eli Lilly Japan, and Taisho Toyama Pharmaceutical.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Document is current

Any future updates will be listed below